ReviewFrontiers in medicine2023
Hyperkalemia in CKD: an overview of available therapeutic strategies.
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Incidence of hyperkalemia RAASi and SGLT-2i treatment in individuals with diabetic kidney disease: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Clinical impact of an EHR-integrated hyperkalemia management system: a real-world study of 10,934 episodes.Renal failure · 2026Article
- Fruits, Vegetables, and Legumes: Harnessing the Gut-Kidney Axis in Hypertensive Chronic Kidney Disease.Foods (Basel, Switzerland) · 2026Review
- Impact of Duration of Outpatient Sodium Zirconium Cyclosilicate Therapy on Hyperkalemia-Related Health Care Resource Utilization: A Matched Cohort Analysis.Kidney medicine · 2026Article
- Efficacy of Patiromer in Treatment of Long Inter-Dialytic Interval Hyperkalemia in Potassium-Rich Diet Populations Undergoing Intermittent Hemodialysis.International journal of nephrology and renovascular disease · 2026Article
- Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study.Drug design, development and therapy · 2026Article
- Comprehensive Management of Hyperkalaemia in Patients with Chronic Kidney Disease and Cardiovascular Conditions: Expert Recommendations from Mexico.Cardiac failure review · 2026Review
- Article
- Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies.Journal of clinical medicine · 2025Review
- Review
- The Interplay Between Carotid Intima-Media Thickness and Selected Serum Biomarkers in Various Stages of Chronic Kidney Disease.Biomedicines · 2025Article
- Minerals and Human Health: From Deficiency to Toxicity.Nutrients · 2025Review
- Relationship between different diet indices and frailty and mortality in population with CKD.Frontiers in nutrition · 2025Article
- Article
- Role of Nutrients in Pediatric Non-Dialysis Chronic Kidney Disease: From Pathogenesis to Correct Supplementation.Biomedicines · 2024Review
- Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.International journal of nephrology and renovascular disease · 2024Article
- Effects of salt substitute on urinary electrolytes and blood pressure in a real-world setting-cohort study in Hunan, China.Frontiers in nutrition · 2024Article
- Patient Characteristics and Outcomes of Hospitalized Chronic Kidney Disease Patients with and without Type 2 Diabetes Mellitus: Observations from the German Claims Data-Based Cohort of the CaReMe-CKD Multinational Study.Clinical epidemiology · 2024Article
- Pioglitazone treatment mitigates cardiovascular bioprosthetic degeneration in a chronic kidney disease model.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperkalemia (HK) is a life-threatening condition that often occurs in patients with chronic kidney disease (CKD). High serum potassium (sKsK) is responsible for a higher risk of end-stage renal disease, arrhythmias and mortality. This risk increases in patients that discontinue cardio-nephroprotective renin-angiotensin-aldosterone system inhibitor (RAASi) therapy after developing HK. Hence, the management of HK deserves the attention of the clinician in order to optimize the therapeutic strategies of chronic treatment of HK in the CKD patient. The adoption in clinical practice of the new hypokalaemic agents patiromer and sodium zirconium cyclosilicate (SZC) for the prevention and chronic treatment of HK could allow patients, suffering from heart failure and chronic renal failure, to continue to benefit from RAASi therapy. We have updated a narrative review of the clear variables, correct definition, epidemiology, pathogenesis, etiology and classifications for HK among non-dialysis CKD (ND CKD) patients. Furthermore, by describing the prognostic impact on mortality and on the progression of renal damage, we want to outline the strategies currently available for the control of potassium (K+) plasma levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.